[18F]PEG-Folate PET-CT imaging for monitoring of therapy response in Rheumatoid Arthritis patients - Monitoring of therapy response with PET-CT imaging in RA

Vrije Universiteit Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients must be at least 30 years of age
•Diagnosis of rheumatoid arthritis according to the 1987 revised criteria of
•the American Rheumatism Association (ARA)13 and/or the 2010 ACR/EULAR
•Rheumatoid Arthritis classification criteria.
•Patients with clinically active disease as assessed by a physician; with
•arthritis in at least one synovial biopsy accessible joint and have a clinical
•indication to start or restart (if stopped >12 weeks) with anti-TNF (either
•Infliximab, Etanercept, Adalimumab or Certolizumab).
•Prior treatment with one anti-TNF agent (Adalimumab, Certolizumab,
•Etanercept, Golimumab or Infliximab) is permitted, but may not be a primary
•failure to any anti-TNF agent (defined as no response within the first 12 weeks
•of treatment)
•Treatment with disease modifying anti-rheumatic drugs (DMARDS) and oral
•corticosteroid up to 10 mg daily is allowed, provided that there is a stable
•dose for at least 4 weeks prior to inclusion and during the study up to 12
•weeks of follow up.
•Non-steroidal anti-inflammatory drugs (NSAID) is permitted, provided that
•there is a stable dose for at least 4 weeks prior to inclusion and during the
•study up to 12 weeks of follow up.
•Patients must be able to adhere to the study appointments and other protocol
•requirements
•Patients must be capable of giving informed consent and the consent must have
•been obtained prior to the study related procedures.

发起方